



## Pilot and Exploratory Study Proposals from the [Cancer Targeting and Therapeutics Program](#) at the University of Florida Health Cancer Center

**Release Date: Sep 16, 2024**

**Information session during CTT bimonthly program meeting on Oct 3, 2024, 3:00 PM**

Meeting URL: <https://ufl.zoom.us/j/99591631621>

Meeting ID: 995 9163 1621

Passcode: -----

**Full Application due Nov 15, 2024**

The UFHCC's **Cancer Targeting and Therapeutics Program (CTT)** Program is seeking innovative, interdisciplinary Pilot and Exploratory Studies applications, in alignment with CTT's programmatic aims. Successful applications should collect pilot data that will lead to extramural research grants and/or career development awards. Examples of proposals consistent with this opportunity include (but are not limited to) support for:

- Generating preliminary data necessary for applying to collaborative, cooperative, or large-scale translational extramural research initiatives.
- Alignment with CTT aims: i) Discover and develop Targeted therapeutics; ii) Identify and develop biomarkers, assay and tools to improve therapeutics and iii) translation of novel concepts for therapeutic improvement.
- Interdisciplinary collaborations between UFHCC- GNV and UF Scripps
- Research initiatives relevant to UFHCC's catchment area.

### **Who should apply? What types of projects are funded? What are the evaluation criteria?**

Interdisciplinary research studies are encouraged and they may originate from investigators at any College within the University of Florida, and UF Scripps. These studies may be led by early-stage or senior investigators. Proposals will be evaluated on the basis of:

1. Significance, methodological approach, scientific merit and innovation
2. Potential to result in subsequent larger NIH funded projects. A paragraph is required to describe the aims of the subsequent project and to outline how the PES will provide data that are needed for the major grant.
3. Environment and use of UFHCC/UF Scripps Shared Resources
4. Budget and timeline appropriateness
5. For ESI targeted application: Early-Stage Investigator Involvement and level of mentoring offered to Early-Stage Investigators

### **What are the budgetary allowances?**

1. Up to \$50,000 total in direct costs only. It is the expectation that all funds will be expended within the award year. Approved NCE's will allow carryover of funds with approved scientific justification. Funding is anticipated for up to 2 proposals.
2. With clinical components, the budget is eligible for 2 years to allow time for patient/sample accruals.
3. Priority will be given to applications that are completed within a shorter timeline. Therefore, budget and timeline appropriateness are a key basis for evaluation of the application.

### **ALLOWABLE COSTS**

1. Only direct costs that support the advancement of the Specific Aims are allowed.
2. Funds awarded may not be used for indirect costs.
3. Awardees must comply with the broad policies governing Cost Accounting Standards and the Cancer Center's [Pilot Allowable Cost list](#).



## PROVISIONS APPLICABLE TO DIRECT COSTS

1. Postdoctoral fellow, staff scientists, and staff salaries and graduate student stipends are allowed
2. Principal Investigator and key personnel salaries are not permitted.
3. Supplies required for the project are allowed. Please indicate nature of supplies and justification.
4. Travel is not permitted.
5. General purpose office equipment is not allowed.
6. Food is not allowed, except for research purposes for research study participants.

## Will support from other entities enhance the potential for funding?

Leveraging funding from this award by combining resources from other entities is encouraged but not required.

## When will applicants receive notification of award?

Notification of award is expected by **January 1, 2025** and funds will be distributed **in the Spring of 2025**. The distribution of awards is contingent upon approval of the project from the local Institutional Review Board (IRB) and/or IACUC, as applicable. **Applicants must ensure and/or include in their timeline the IRB submission process.** Facilitation of the IRB process is encouraged by speaking directly with appropriate IRB official regarding a specific application.

## What is the application process?

Full Application using the template found [here](#) and guidelines found [here](#) is due by **Nov 15, 2024**.

## Publication Acknowledgement

Dissemination of the results developed under this award are encouraged to be made publicly available and published in scholarly journals. All publications shall acknowledge that “**Research reported in this publication was supported by the UF Health Cancer Center, supported in part by state appropriations provided in [Fla. Stat. § 381.915](#) and the National Cancer Institute of the National Institutes of Health under Award Number P30CA247796. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the State of Florida.**” and must be in PMCID compliance.

For additional information or clarification, please contact Drs. Spicer or Lamba for guidance in developing relevant project proposals. e-mails: [jatinderklamba@ufl.edu](mailto:jatinderklamba@ufl.edu); [spicert@ufl.edu](mailto:spicert@ufl.edu); [ResearchAdmin@cancer.ufl.edu](mailto:ResearchAdmin@cancer.ufl.edu)